The Enduring Success of Hybridoma-based Antibody Development
White Paper Aug 14, 2019
Since its original development in 1975, hybridoma technology encourages researchers all over the world to share their antibodies with one another, unlocking a vast amount of potential for biological research.
Due to their high selectivity, monoclonal antibodies (mAbs) are used in a wide range of disciplines, including research, diagnostics and therapeutic applications. Despite the advancement of modern antibody generation technologies, hybridoma-based antibody production continues to be a leading approach for mAb discovery and development.
Download these whitepapers to explore:
- The key benefits of using hybridoma-based antibody development
- Perceived misconceptions relating to hybridoma technology
- Alternative approaches that currently exist for mAb generation
Related White Papers
This document describes how Malvern Panalytical systems support system owners, meeting the requirements of the 21 CFR Part 11 regulations issued by the United States’ FDA.
READ MOREDownload this white paper to understand how PerkinElmer’s Lead Discovery Premium can help deliver unified, interactive, responsive, data-agnostic access to all users.
READ MOREDownload this whitepaper to explore the shortcomings of LIMS when it comes to managing microbiology processes and learn of ways to overcome associated challenges.
READ MORELike what you just read? You can find similar content on the communities below.
Biopharma Cell Science Immunology & MicrobiologyTo personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free
LOGIN SUBSCRIBE FOR FREE
